Trial · NCT07472647
SYS6090 Combination Therapy in Advanced Lung Cancer
NCT07472647, Phase 1, Phase 2, Not yet recruiting, Shanghai JMT-Bio Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. SYS6090 Combination Therapy in Advanced Lung Cancer. Trials, record NCT07472647. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07472647
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SYS6090 Combination Therapy in Advanced Lung Cancer
- NCT number
- NCT07472647
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 596 participants, estimated
- Lead sponsor
- Shanghai JMT-Bio Inc.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Interventions
SYS6090 + pemetrexed + platinum-based chemotherapy, SYS6090 + paclitaxel + platinum-based chemotherapy, SYS6090 + docetaxel, SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy, SYS6090 + SYS6010, SYS6090 + etoposide + platinum-based chemotherapy, SYS6090 + chemotherapy or other anticancer therapy
- First posted
- 2026-03-16
- Last updated
- 2026-03-16
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicity (DLT) (Phase Ib) | Approximately 21 days. | To evaluate the safety of SYS6090 in participants. |
| Primary | Adverse Events (AEs) (Phase Ib) | Up to 90 days after the last administration | To evaluate the safety of SYS6090 combination therapy in participants. |
| Primary | Objective response rate (ORR) (Phase II) | Through out the study (up to 2 years) | ORR is defined as the proportion of participants in whom a complete response (CR) or partial response (PR), per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 is observed as best overall response. |
| Secondary | Cmax of SYS6090 (and SYS6010 if applicable) | Through out the study (up to 2 years) | To evaluate the systemic pharmacokinetics of SYS6090 (and SYS6010 if applicable). |
| Secondary | AUC0-t of SYS6090 (and SYS6010 if applicable) | Through out the study (up to 2 years) | To evaluate the systemic pharmacokinetics of SYS6090 (and SYS6010 if applicable） |
| Secondary | Clearance (CL) of SYS6090 (and SYS6010 if applicable) | Through out the study (up to 2 years) | To evaluate the systemic pharmacokinetics of SYS6090 (and SYS6010 if applicable) |
| Secondary | Other Efficacy Endpoints Assessed by RECIST v1.1 (DoR, DCR, TTR, PFS, and OS) | Through out the study (up to 2 years) | Evaluation of other efficacy endpoints of SYS6090 combination therapy in participants with advanced lung cancer, assessed by the investigator according to RECIST v1.1, including duration of response (DoR), disease control rate (DCR), time to response (TTR), progression-free survival (PFS), and overall survival (OS). |
| Secondary | Adverse Events (AEs) (Phase II) | Through out the study (up to 2 years) | To evaluate the safety of SYS6090 combination therapy in participants |
| Secondary | Correlation between Biomarker Levels and Preliminary Efficacy | Through out the study (up to 2 years) | The Correlation between Baseline PD-L1 Expression and Antitumor Activity |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07472647
GET https://conductscience.org/api/trials/v1/NCT07472647/registered